Review



polyclonal goat anti human mfsd2a antibody  (ProSci Incorporated)


Bioz Verified Symbol ProSci Incorporated is a verified supplier
Bioz Manufacturer Symbol ProSci Incorporated manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    ProSci Incorporated polyclonal goat anti human mfsd2a antibody
    Decreased expression of <t>MFSD2A</t> in HCC. ( A ) The expression of MFSD2A in HCC and normal liver tissues was analyzed in the TCGA and GTEx databases ( P < 0.01). ( B ) RT-qPCR showed that the relative mRNA expression of MFSD2A in HCC tissues was decreased compared with that in the matched adjacent nontumorous tissues (n = 24, *P = 0.016). ( C ) Densitometric analysis of MFSD2A protein levels relative to GAPDH in HCC and corresponding normal liver samples. The expression of MFSD2A was reduced in tumor tissues when compared with that in corresponding nontumorous tissues (n = 11, *P = 0.0472). ( D ) The protein level of MFSD2A in HCC and corresponding nontumorous specimens was tested by western blotting. GAPDH was used as a loading control. RT-qPCR ( E ) and western blotting ( F ) were used to analyze the expression of MFSD2A in several HCC cell lines and one immortalized hepatic cell line LO2.
    Polyclonal Goat Anti Human Mfsd2a Antibody, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti human mfsd2a antibody/product/ProSci Incorporated
    Average 90 stars, based on 2 article reviews
    polyclonal goat anti human mfsd2a antibody - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "The prognostic value of major facilitator superfamily domain-containing protein 2A in patients with hepatocellular carcinoma"

    Article Title: The prognostic value of major facilitator superfamily domain-containing protein 2A in patients with hepatocellular carcinoma

    Journal: Aging (Albany NY)

    doi: 10.18632/aging.102333

    Decreased expression of MFSD2A in HCC. ( A ) The expression of MFSD2A in HCC and normal liver tissues was analyzed in the TCGA and GTEx databases ( P < 0.01). ( B ) RT-qPCR showed that the relative mRNA expression of MFSD2A in HCC tissues was decreased compared with that in the matched adjacent nontumorous tissues (n = 24, *P = 0.016). ( C ) Densitometric analysis of MFSD2A protein levels relative to GAPDH in HCC and corresponding normal liver samples. The expression of MFSD2A was reduced in tumor tissues when compared with that in corresponding nontumorous tissues (n = 11, *P = 0.0472). ( D ) The protein level of MFSD2A in HCC and corresponding nontumorous specimens was tested by western blotting. GAPDH was used as a loading control. RT-qPCR ( E ) and western blotting ( F ) were used to analyze the expression of MFSD2A in several HCC cell lines and one immortalized hepatic cell line LO2.
    Figure Legend Snippet: Decreased expression of MFSD2A in HCC. ( A ) The expression of MFSD2A in HCC and normal liver tissues was analyzed in the TCGA and GTEx databases ( P < 0.01). ( B ) RT-qPCR showed that the relative mRNA expression of MFSD2A in HCC tissues was decreased compared with that in the matched adjacent nontumorous tissues (n = 24, *P = 0.016). ( C ) Densitometric analysis of MFSD2A protein levels relative to GAPDH in HCC and corresponding normal liver samples. The expression of MFSD2A was reduced in tumor tissues when compared with that in corresponding nontumorous tissues (n = 11, *P = 0.0472). ( D ) The protein level of MFSD2A in HCC and corresponding nontumorous specimens was tested by western blotting. GAPDH was used as a loading control. RT-qPCR ( E ) and western blotting ( F ) were used to analyze the expression of MFSD2A in several HCC cell lines and one immortalized hepatic cell line LO2.

    Techniques Used: Expressing, Quantitative RT-PCR, Western Blot, Control

    MFSD2A expression and clinical values. ( A , B ) High expression level of MFSD2A (200×magnification); ( C ) low expression level of MFSD2A (200×magnification); ( D ) negative expression of MFSD2A (200×magnification). Low expression of MFSD2A was significantly correlated with tumor grade ( E ) and stage ( F ) analyzed with UALCAN database. The lower expression level of MFSD2A represented higher stage and pathological grade. ( G ) Patients expressing higher levels of MFSD2A show significantly better five-year overall survival ( P = 0.021). Survival curves of 79 HCC patients with different MFSD2A expression are shown. Kaplan-Meier survival curves for high expression of MFSD2A group were significantly different ( P =0.021, log-rank test) from low MFSD2A expression group in 79 HCC patients. Diagnostic outcomes for plasma MFSD2A in the diagnosis of HCC ( H ) MFSD2A concentrations in plasma. ( I ) ROC curve for MFSD2A with HCC versus HC and CHB. MFSD2A=Major Facilitator Superfamily Domain Containing 2A, HCC=hepatocellular carcinoma, CHB=chronic hepatitis B virus infection, HC=healthy control.
    Figure Legend Snippet: MFSD2A expression and clinical values. ( A , B ) High expression level of MFSD2A (200×magnification); ( C ) low expression level of MFSD2A (200×magnification); ( D ) negative expression of MFSD2A (200×magnification). Low expression of MFSD2A was significantly correlated with tumor grade ( E ) and stage ( F ) analyzed with UALCAN database. The lower expression level of MFSD2A represented higher stage and pathological grade. ( G ) Patients expressing higher levels of MFSD2A show significantly better five-year overall survival ( P = 0.021). Survival curves of 79 HCC patients with different MFSD2A expression are shown. Kaplan-Meier survival curves for high expression of MFSD2A group were significantly different ( P =0.021, log-rank test) from low MFSD2A expression group in 79 HCC patients. Diagnostic outcomes for plasma MFSD2A in the diagnosis of HCC ( H ) MFSD2A concentrations in plasma. ( I ) ROC curve for MFSD2A with HCC versus HC and CHB. MFSD2A=Major Facilitator Superfamily Domain Containing 2A, HCC=hepatocellular carcinoma, CHB=chronic hepatitis B virus infection, HC=healthy control.

    Techniques Used: Expressing, Diagnostic Assay, Clinical Proteomics, Biomarker Discovery, Virus, Infection, Control

    Relationship between MFSD2A expression and clinicopathological features of hepatocellular carcinoma patients.
    Figure Legend Snippet: Relationship between MFSD2A expression and clinicopathological features of hepatocellular carcinoma patients.

    Techniques Used: Expressing

    Univariate and multivariate analyses showing the overall survival rate for hepatocellular patients.
    Figure Legend Snippet: Univariate and multivariate analyses showing the overall survival rate for hepatocellular patients.

    Techniques Used: Expressing



    Similar Products

    polyclonal goat anti human mfsd2a antibody  (ProSci Incorporated)
    90
    ProSci Incorporated polyclonal goat anti human mfsd2a antibody
    Decreased expression of <t>MFSD2A</t> in HCC. ( A ) The expression of MFSD2A in HCC and normal liver tissues was analyzed in the TCGA and GTEx databases ( P < 0.01). ( B ) RT-qPCR showed that the relative mRNA expression of MFSD2A in HCC tissues was decreased compared with that in the matched adjacent nontumorous tissues (n = 24, *P = 0.016). ( C ) Densitometric analysis of MFSD2A protein levels relative to GAPDH in HCC and corresponding normal liver samples. The expression of MFSD2A was reduced in tumor tissues when compared with that in corresponding nontumorous tissues (n = 11, *P = 0.0472). ( D ) The protein level of MFSD2A in HCC and corresponding nontumorous specimens was tested by western blotting. GAPDH was used as a loading control. RT-qPCR ( E ) and western blotting ( F ) were used to analyze the expression of MFSD2A in several HCC cell lines and one immortalized hepatic cell line LO2.
    Polyclonal Goat Anti Human Mfsd2a Antibody, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal goat anti human mfsd2a antibody/product/ProSci Incorporated
    Average 90 stars, based on 1 article reviews
    polyclonal goat anti human mfsd2a antibody - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Decreased expression of MFSD2A in HCC. ( A ) The expression of MFSD2A in HCC and normal liver tissues was analyzed in the TCGA and GTEx databases ( P < 0.01). ( B ) RT-qPCR showed that the relative mRNA expression of MFSD2A in HCC tissues was decreased compared with that in the matched adjacent nontumorous tissues (n = 24, *P = 0.016). ( C ) Densitometric analysis of MFSD2A protein levels relative to GAPDH in HCC and corresponding normal liver samples. The expression of MFSD2A was reduced in tumor tissues when compared with that in corresponding nontumorous tissues (n = 11, *P = 0.0472). ( D ) The protein level of MFSD2A in HCC and corresponding nontumorous specimens was tested by western blotting. GAPDH was used as a loading control. RT-qPCR ( E ) and western blotting ( F ) were used to analyze the expression of MFSD2A in several HCC cell lines and one immortalized hepatic cell line LO2.

    Journal: Aging (Albany NY)

    Article Title: The prognostic value of major facilitator superfamily domain-containing protein 2A in patients with hepatocellular carcinoma

    doi: 10.18632/aging.102333

    Figure Lengend Snippet: Decreased expression of MFSD2A in HCC. ( A ) The expression of MFSD2A in HCC and normal liver tissues was analyzed in the TCGA and GTEx databases ( P < 0.01). ( B ) RT-qPCR showed that the relative mRNA expression of MFSD2A in HCC tissues was decreased compared with that in the matched adjacent nontumorous tissues (n = 24, *P = 0.016). ( C ) Densitometric analysis of MFSD2A protein levels relative to GAPDH in HCC and corresponding normal liver samples. The expression of MFSD2A was reduced in tumor tissues when compared with that in corresponding nontumorous tissues (n = 11, *P = 0.0472). ( D ) The protein level of MFSD2A in HCC and corresponding nontumorous specimens was tested by western blotting. GAPDH was used as a loading control. RT-qPCR ( E ) and western blotting ( F ) were used to analyze the expression of MFSD2A in several HCC cell lines and one immortalized hepatic cell line LO2.

    Article Snippet: After washing with PBS, the slide was incubated overnight with polyclonal goat anti-human MFSD2A antibody (Prosci Company, diluted 1/300) at 4°C.

    Techniques: Expressing, Quantitative RT-PCR, Western Blot, Control

    MFSD2A expression and clinical values. ( A , B ) High expression level of MFSD2A (200×magnification); ( C ) low expression level of MFSD2A (200×magnification); ( D ) negative expression of MFSD2A (200×magnification). Low expression of MFSD2A was significantly correlated with tumor grade ( E ) and stage ( F ) analyzed with UALCAN database. The lower expression level of MFSD2A represented higher stage and pathological grade. ( G ) Patients expressing higher levels of MFSD2A show significantly better five-year overall survival ( P = 0.021). Survival curves of 79 HCC patients with different MFSD2A expression are shown. Kaplan-Meier survival curves for high expression of MFSD2A group were significantly different ( P =0.021, log-rank test) from low MFSD2A expression group in 79 HCC patients. Diagnostic outcomes for plasma MFSD2A in the diagnosis of HCC ( H ) MFSD2A concentrations in plasma. ( I ) ROC curve for MFSD2A with HCC versus HC and CHB. MFSD2A=Major Facilitator Superfamily Domain Containing 2A, HCC=hepatocellular carcinoma, CHB=chronic hepatitis B virus infection, HC=healthy control.

    Journal: Aging (Albany NY)

    Article Title: The prognostic value of major facilitator superfamily domain-containing protein 2A in patients with hepatocellular carcinoma

    doi: 10.18632/aging.102333

    Figure Lengend Snippet: MFSD2A expression and clinical values. ( A , B ) High expression level of MFSD2A (200×magnification); ( C ) low expression level of MFSD2A (200×magnification); ( D ) negative expression of MFSD2A (200×magnification). Low expression of MFSD2A was significantly correlated with tumor grade ( E ) and stage ( F ) analyzed with UALCAN database. The lower expression level of MFSD2A represented higher stage and pathological grade. ( G ) Patients expressing higher levels of MFSD2A show significantly better five-year overall survival ( P = 0.021). Survival curves of 79 HCC patients with different MFSD2A expression are shown. Kaplan-Meier survival curves for high expression of MFSD2A group were significantly different ( P =0.021, log-rank test) from low MFSD2A expression group in 79 HCC patients. Diagnostic outcomes for plasma MFSD2A in the diagnosis of HCC ( H ) MFSD2A concentrations in plasma. ( I ) ROC curve for MFSD2A with HCC versus HC and CHB. MFSD2A=Major Facilitator Superfamily Domain Containing 2A, HCC=hepatocellular carcinoma, CHB=chronic hepatitis B virus infection, HC=healthy control.

    Article Snippet: After washing with PBS, the slide was incubated overnight with polyclonal goat anti-human MFSD2A antibody (Prosci Company, diluted 1/300) at 4°C.

    Techniques: Expressing, Diagnostic Assay, Clinical Proteomics, Biomarker Discovery, Virus, Infection, Control

    Relationship between MFSD2A expression and clinicopathological features of hepatocellular carcinoma patients.

    Journal: Aging (Albany NY)

    Article Title: The prognostic value of major facilitator superfamily domain-containing protein 2A in patients with hepatocellular carcinoma

    doi: 10.18632/aging.102333

    Figure Lengend Snippet: Relationship between MFSD2A expression and clinicopathological features of hepatocellular carcinoma patients.

    Article Snippet: After washing with PBS, the slide was incubated overnight with polyclonal goat anti-human MFSD2A antibody (Prosci Company, diluted 1/300) at 4°C.

    Techniques: Expressing

    Univariate and multivariate analyses showing the overall survival rate for hepatocellular patients.

    Journal: Aging (Albany NY)

    Article Title: The prognostic value of major facilitator superfamily domain-containing protein 2A in patients with hepatocellular carcinoma

    doi: 10.18632/aging.102333

    Figure Lengend Snippet: Univariate and multivariate analyses showing the overall survival rate for hepatocellular patients.

    Article Snippet: After washing with PBS, the slide was incubated overnight with polyclonal goat anti-human MFSD2A antibody (Prosci Company, diluted 1/300) at 4°C.

    Techniques: Expressing